Apogee Therapeutics (APGE) Cash & Equivalents (2022 - 2026)

Apogee Therapeutics (APGE) has reported Cash & Equivalents for 5 consecutive years, with $451.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 322.57% year-over-year to $451.8 million; the TTM figure through Mar 2026 stood at $451.8 million (up 322.57% YoY), while the FY2025 annual figure was $131.5 million, down 7.22% from the prior year.
• Cash & Equivalents improved to $451.8 million in Q1 2026 per APGE's latest filing, from $131.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $485.5 million in Q1 2024 and bottomed at $5.0 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $183.2 million across 5 years, with a median of $128.3 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents jumped 2414.46% — and 2025, when it slumped 77.98%.
• Apogee Therapeutics' Cash & Equivalents stood at $151.9 million in 2022, then declined by 22.1% to $118.3 million in 2023, then advanced by 19.84% to $141.8 million in 2024, then decreased by 7.22% to $131.5 million in 2025, then jumped by 243.44% to $451.8 million in 2026.
• Business Quant data shows APGE's Cash & Equivalents at $451.8 million in Q1 2026, $131.5 million in Q4 2025, and $107.9 million in Q3 2025.